• Radioiodinated Balsalazide: A Selective Tracer for Colitis I

  2026-05-06

  This study presents the synthesis and evaluation of radioiodinated balsalazide as a highly selective radiotracer for imaging ulcerative colitis in mice. The protocol achieves high labeling efficiency, radiochemical purity, and demonstrates strong colonic uptake in disease models, supporting advanced inflammation research workflows.

• Biochemical Functions of CARMIL’s Membrane-Binding Domain in

  2026-05-06

  This study elucidates the multifaceted regulatory mechanisms of the CARMIL membrane-binding (MB) domain in actin filament dynamics. By dissecting domain-specific actions, the authors show that the MB domain not only targets capping protein (CP) to the membrane but also modulates CP activation and release, resolving long-standing questions about actin assembly regulation at membrane interfaces.

• Tropifexor (LJN452): Potent FXR Agonist for Intestinal Barri

  2026-05-05

  Tropifexor (LJN452) is a highly potent Farnesoid X Receptor (FXR) agonist with sub-nanomolar EC50, widely used in studies of intestinal epithelial barrier function and metabolic disease models. Recent peer-reviewed research demonstrates that Tropifexor markedly improves epithelial barrier integrity and defense responses in neonatal piglets receiving parenteral nutrition. APExBIO supplies Tropifexor for research use, supporting robust FXR signaling pathway modulation.

• STING Agonist-1: Unlocking B Cell Activation in Cancer Resea

  2026-05-05

  STING agonist-1, a high-purity small molecule from APExBIO, empowers immunology and cancer researchers to dissect STING–CD40–TRAF2–IRF4 signaling and precisely modulate innate immune activation. This article provides experimental workflows, troubleshooting insights, and actionable guidance for leveraging STING agonist-1 in advanced tumor immunology studies.

• Tofacitinib Citrate: Optimized Workflows in Immune Regulatio

  2026-05-04

  Tofacitinib citrate (CP-690550 citrate) stands out for its nanomolar JAK3 selectivity, enabling precise dissection of immune pathways in inflammatory disease models. This article translates comparative endothelial findings into robust protocols, troubleshooting strategies, and advanced applications for reproducible immune regulation research.

• Reliable Cell Assays with HRP Rabbit Anti-Goat IgG (H+L) Ant

  2026-05-04

  This article provides protocol-driven insights on overcoming common immunodetection challenges in cell viability and toxicity assays. It demonstrates how the HRP Rabbit Anti-Goat IgG (H+L) Antibody (SKU K1224) from APExBIO delivers reproducible, high-sensitivity detection for goat primary antibodies. Evidence-based scenario Q&As guide selection, optimization, and interpretation in real-world laboratory settings.

• Rapamycin (Sirolimus): mTOR Inhibition for Autophagy and Lip

  2026-05-03

  Rapamycin (Sirolimus) from APExBIO delivers high specificity and reproducibility in mTOR pathway inhibition, enabling precise modulation of autophagy and lipid metabolism in both mammalian and aquatic cell models. New workflows harnessing its potent IC50 and solubility profile unlock advanced lipidomic and cell viability assays, with optimized troubleshooting strategies for complex experimental designs.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody: Technical Guidance

  2026-05-02

  The Cy3 Goat Anti-Mouse IgG (H+L) Antibody enables sensitive and specific detection of mouse immunoglobulins in immunofluorescence, flow cytometry, and western blotting workflows. It is best suited for research applications requiring fluorescence-based signal amplification, but is not intended for diagnostic or medical use. Use is not recommended where cross-reactivity with non-mouse species is a concern or when non-fluorescent detection systems are needed.

• Disrupting PD-L1 Recycling in Myeloid Cells Boosts T-Cell Ex

  2026-05-01

  This study introduces a novel anti-PD-L1 antibody (H1A) that targets PD-L1 recycling and degradation in myeloid cells, overcoming key limitations of current checkpoint inhibitors. By redirecting PD-L1 for degradation, H1A enhances myeloid cell activation and expands cytotoxic T-cell populations, offering a new strategy to improve immune responses in cancers resistant to existing therapies.

• Tacrolimus (FK506): Precision in Translational Immune Modula

  2026-05-01

  Discover how Tacrolimus (FK506) enables highly selective and potent immune response suppression for translational researchers. This article integrates mechanistic insights, protocol guidance, and strategic comparisons—highlighting APExBIO's Tacrolimus (FK506) as the platform of choice for advanced transplantation immunology research and autoimmune disease models.

• FOXM1–ERα ceRNA Network in Female Lung Adenocarcinoma: Insig

  2026-04-30

  This study uncovers a novel ceRNA network involving FOXM1 and estrogen receptor alpha (ERα) in female lung adenocarcinoma (LUAD), integrating large-scale transcriptomic analyses and in vitro validation. These findings provide mechanistic insight into LUAD progression and suggest new biomarker and therapeutic avenues for hormone receptor-driven lung cancer.

• PPM-18 Unlocks Precision iNOS Inhibition in Sepsis Research

  2026-04-30

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) enables highly selective NF-κB pathway inhibition for advanced sepsis and inflammation models. Its unique mechanism allows researchers to dissect iNOS regulation with unprecedented reproducibility and workflow flexibility.

• MOG (35-55) Peptide: Molecular Control Points in EAE and MS

  2026-04-29

  Explore the molecular intricacies of MOG (35-55), a myelin oligodendrocyte glycoprotein peptide, as a precision tool in autoimmune encephalomyelitis research. This article uniquely bridges mechanistic immunology and assay optimization, providing advanced insights for multiple sclerosis research.

• Balsalazide Disodium: Applied Protocols in Inflammation Rese

  2026-04-29

  Balsalazide Disodium Dihydrate empowers precise modeling of ulcerative colitis and targeted inflammation workflows, with robust radiolabeling and immunology assay compatibility. Discover actionable protocol enhancements and troubleshooting strategies to maximize reproducibility in preclinical and translational inflammation research.

• JNK-IN-7 as a Precision Tool for Dissecting JNK-ERK Pathways

  2026-04-28

  Explore how JNK-IN-7, a selective JNK inhibitor, uniquely enables advanced mechanistic research into apoptosis and innate immune signaling. This article provides a deep, assay-focused perspective distinct from previous analyses.

8434 records 22/563 page Previous Next First page 上5页 2122232425 下5页 Last page